000			01972 a2200541 4500
005			20250514223806.0
264		0	_c20050624
008			200506s 0 0 eng d
022			_a0028-3908
024	7		_a10.1016/j.neuropharm.2004.10.019 _2doi
040			_aNLM _beng _cNLM
100	1		_aMoroni, F
245	0	0	_aKynurenine 3-mono-oxygenase inhibitors reduce glutamate concentration in the extracellular spaces of the basal ganglia but not in those of the cortex or hippocampus. _h[electronic resource]
260			_bNeuropharmacology _cMay 2005
300			_a788-95 p. _bdigital
500			_aPublication Type: Comparative Study; Journal Article
650	0	4	_aAnimals
650	0	4	_aAvoidance Learning _xdrug effects
650	0	4	_aBasal Ganglia _xdrug effects
650	0	4	_aBehavior, Animal _xdrug effects
650	0	4	_aBrain Chemistry _xdrug effects
650	0	4	_aCalcium Channel Blockers _xpharmacology
650	0	4	_aChromatography, High Pressure Liquid _xmethods
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aDrug Interactions
650	0	4	_aExtracellular Space _xdrug effects
650	0	4	_aGlutamic Acid _xmetabolism
650	0	4	_aKynurenic Acid _xmetabolism
650	0	4	_aKynurenine 3-Monooxygenase
650	0	4	_aMale
650	0	4	_aMicrodialysis _xmethods
650	0	4	_aMixed Function Oxygenases _xantagonists & inhibitors
650	0	4	_aPotassium Chloride _xpharmacology
650	0	4	_aRats
650	0	4	_aRats, Wistar
650	0	4	_aStatistics, Nonparametric
650	0	4	_aSulfonamides _xpharmacology
650	0	4	_aThiazoles _xpharmacology
650	0	4	_aTime Factors
650	0	4	_aomega-Conotoxin GVIA _xpharmacology
700	1		_aCozzi, A
700	1		_aCarpendo, R
700	1		_aCipriani, G
700	1		_aVeneroni, O
700	1		_aIzzo, E
773	0		_tNeuropharmacology _gvol. 48 _gno. 6 _gp. 788-95
856	4	0	_uhttps://doi.org/10.1016/j.neuropharm.2004.10.019 _zAvailable from publisher's website
999			_c15497869 _d15497869